Prevention strategies for ovarian cancer: Current possibilities and perspectives

被引：0
作者：
Baumann K.H. [1 ,2 ]
Wagner U. [1 ]
机构：
[1] Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Universitätsklinikum Gießen und Marburg
[2] Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, 35043 Marburg, Baldingerstr.
来源：
Der Gynäkologe | 2008年 / 41卷 / 7期
关键词：
Bilateral salpingo-oophorectomy; Hormonal contraception; Ovarian cancer; Prevention; Screening;
D O I：
10.1007/s00129-008-2143-7
中图分类号：
学科分类号：
摘要：
Ovarian cancer is most often diagnosed at an advanced disease stage with reduced or poor prognosis. This fatal course of disease might be influenced by preventive and screening measures. Characterization and identification of populations especially at risk, promotion of already known preventive strategies, improvement of diagnostic tools, and evaluation of new compounds and potential screening instruments are some aspects for discussion. Hormonal contraception, other endocrine therapies and chemopreventive agents, and surgical interventions are critically reviewed. Factors increasing the nonhereditary risk for ovarian cancer are considered. Today, intervention and avoidance strategies are available to influence the ovarian cancer risk; these should be combined with appropriate diagnostic procedures. Secondary and tertiary prevention in ovarian cancer is discussed. © 2008 Springer Medizin Verlag.
引用
收藏
页码：513 / 522
页数：9
相关论文
共 129 条
[71]  
Wu, Int J Gynecol Cancer, 18, (2008)
[72]  
Matsuyama M., Yoshimura R., Peroxisome Proliferator-Activated Receptor-gamma Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer, PPAR Res, 2008, (2008)
[73]  
Takahashi, J Pharmacol Sci, 105, (2007)
[74]  
Sertznig, J Cell Physiol, 212, (2007)
[75]  
Roukos, Nat Clin Pract Oncol, 4, (2007)
[76]  
Li Y.F., Hu W., Fu S.Q., Et al., Aromatase inhibitors in ovarian cancer: Is there a role?, Int J Gynecol Cancer, (2007)
[77]  
Papadimitriou, Oncology, 66, (2004)
[78]  
Balbi, Int J Gynecol Cancer, 14, (2004)
[79]  
Du, Ann Oncol, 13, (2002)
[80]  
Grundker, J Clin Endocrinol Metab, 87, (2002)
3456789101112